Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

43.89 +0.37 (+0.85%)
Streaming Delayed Price Updated: 2:49 PM EDT, Jul 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharma

< Previous 1 2 3 4 5 6 7 Next >
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
Via Benzinga
Amphastar Receives FDA Approval for Ganirelix Acetate Injection
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier. 
Via Investor's Business Daily
Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92
On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Earnings Scheduled For March 10, 2022
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91. 
Via Investor's Business Daily
Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating
Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91. 
Via Investor's Business Daily
Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating
Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday. 
Via Investor's Business Daily
7 “A”-Rated Stocks to Ground Your Portfolio
It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating. 
Via InvestorPlace
Amphastar Pharmaceuticals: Q4 Earnings Insights
Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021
Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Earnings Preview For Amphastar Pharmaceuticals
Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement.... 
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021,... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
7 Safe Stocks to Rely On When the Market Swerves
When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential. 
Via InvestorPlace
Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating
The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79. 
Via Investor's Business Daily
Top Russell 2000 Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of security prices that, once recognized, helps traders to make informed trading decisions. Let's look at some Russell 2000 stock opportunities by... 
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 42.8% to $0.6 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a... 
Via Benzinga
32 Stocks Moving In Monday's Mid-Day Session
Gainers FGI Industries Ltd. (NASDAQ: FGI) shares jumped 42.4% to $5.37 after surging 19% on Friday. The company, last week, priced its IPO at $6 per share. Knightscope, Inc. (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Maravai Lifesciences Stock Closes In Technical Benchmark, Hitting 80-Plus RS Rating
One key metric to look for in a stock is 80-plus RS Rating. Maravai Lifesciences stock just hit that mark, with a jump from 71 to 81 Monday. 
Via Investor's Business Daily
Amphastar Receives FDA Tentative Approval for Vasopressin
RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Ligand Pharmaceuticals Sees RS Rating Rise To 92
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate... 
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Amphastar Pharmaceuticals, inc (AMPH) Q3 2021 Earnings Call Transcript
AMPH earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.